http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech to Present at Two Upcoming Investor Conferences
-
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
-
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
-
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
-
PureTech Health (PRTC) Appoints Robert Lyne as Chief Portfolio Officer
-
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
-
PureTech Health plc – Half-Year Report
-
PureTech Health: Notice of Half-Yearly Results
-
PureTech (PRTC) Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
-
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
-
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
-
Results of PureTech's Annual General Meeting
-
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
-
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Ther
-
PureTech Announces Annual Results for Year Ended December 31, 2022
-
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
-
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
-
PureTech Health: Notice of Results
-
Royalty Pharma (RPRX) and PureTech Health (PRTC) Enter KarXT Royalty Agreement for Up to $500M
-
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
-
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
-
PureTech to Present at the Barclays Global Healthcare Conference
-
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impa
-
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
-
PureTech to Present at the SVB Securities Global Biopharma Conference
-
PureTech Health (PRTC) Provides End of Year Update
-
PureTech Provides End of Year Report on Key Progress
-
PureTech's (PRTC) LYT-300 Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
-
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
-
PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
-
PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
-
PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
-
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
-
PureTech to Present at Two Upcoming Investor Conferences
-
PureTech to Present at the Jefferies London Healthcare Conference
-
PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
-
PureTech to Present at the Morgan Stanley Global Healthcare Conference
-
PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022
-
PureTech Health plc – Half-Year Report
-
PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals
-
PureTech Health: Notice of Half-Yearly Results
-
PureTech Health's (PRTC) Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
-
PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
-
PureTech Health's (PRTC) Akili Announces Publication Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate
-
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Followi
-
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
-
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
-
PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
-
Results of Annual General Meeting
-
PureTech Health Plc (PRTC) Announces Phase 2 Results of LYT-100-COV in Post-Acute 'Long' COVID
